Pressures to manage sustainability risks are intensifying on a global scale, and the Pharma industry is no exception. Sustainable Procurement managers are facing urgent challenges to meet stakeholder demands while they transition from the old ‘blockbuster drug’ model to a new competitive landscape.
In addition to risks, such as revenue loss and heightened scrutiny, emerging models are exposing new issues – such as shorter product cycles, customized medicines, emerging markets with lower margins,
and compressed margins in primary markets.